Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor Combination in mCRC
NCT05414461Phase 2Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Mar 2019
- Primary completion
- Oct 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in metastatic colorectal cancer (mCRC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Durable Clinical Benefit. Started Mar 2019; status: completed.
02
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05414461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05414461.